News | January 31, 2007

At Nine Months, SFA Stent Trial Shows Promise for PAD Patients

Feb. 1, 2007 — Cook Medical released nine-month data this week for its PTX Paclitaxel-Eluting Stent (DES) trial, which to date demonstrate no stent fractures. The major adverse event (MAE) rate was equivalent to conventional balloon angioplasty treatment at its six-month follow-up point, as reported by the trial's national principal investigator, Michael Dake, M.D., professor and chairman of the department of radiology at the University of Virginia Health System.

During the International Symposium on Endovascular Therapy (ISET), Dr. Dake, presented important nine-month data on the first 60 patients in the randomized trial examining the safety of using Cook's Zilver PTX stent to treat blockages of the superficial femoral artery (SFA) above the knee. He reported that the Zilver PTX stent displayed a zero-percent fracture rate for 41 lesions at six months and 18 lesions at one year.

It is the first trial ever to investigate whether Paclitaxel-eluting stents can be used to successfully treat peripheral arterial disease (PAD), a seriously under-diagnosed disorder affecting up to 20 percent of the adult population worldwide.

Effectiveness of the device in treating lesions of the SFA will be shown in the pivotal trial, expected to start shortly in the U.S., enrolling 420 patients at 50 sites.

This Cook's Zilver PTX drug-eluting vascular stent is an investigational device not approved for sale in the U.S., but under investigation for use in the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery.

For more information visit www.zilverptxtrial.com or www.cookmedical.com.

Related Content

Intact Vascular Announces $20 Million Series C Financing
News | Stents Peripheral | April 27, 2018
April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million.
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral | July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral | July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral | April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral | March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral | March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral | December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral | December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Technology | Stents Peripheral | April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Overlay Init